Apotea AB (publ)

OM:APOTEA Stock Report

Market Cap: SEK 8.0b

Apotea Future Growth

Future criteria checks 5/6

Apotea is forecast to grow earnings and revenue by 21.6% and 11.5% per annum respectively. EPS is expected to grow by 21.5% per annum. Return on equity is forecast to be 30.4% in 3 years.

Key information

21.6%

Earnings growth rate

21.53%

EPS growth rate

Consumer Retailing earnings growth9.3%
Revenue growth rate11.5%
Future return on equity30.40%
Analyst coverage

Low

Last updated30 Apr 2026

Recent future growth updates

No updates

Recent updates

New Narrative • Jan 27

Rising Online Pharmacy Demand And New Warehouse Capacity Will Support Long Term Earnings

Catalysts About Apotea Apotea operates a Swedish online pharmacy platform that sells prescription medicines, OTC products and traded goods. What are the underlying business or industry changes driving this perspective?
Analysis Article • Jan 22

What You Can Learn From Apotea AB (publ)'s (STO:APOTEA) P/S After Its 28% Share Price Crash

The Apotea AB (publ) ( STO:APOTEA ) share price has fared very poorly over the last month, falling by a substantial...
Analysis Article • Jan 21

Why We Like The Returns At Apotea (STO:APOTEA)

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...
Analysis Article • Jul 17

Apotea AB (publ) (STO:APOTEA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Key Insights Apotea's estimated fair value is kr174 based on 2 Stage Free Cash Flow to Equity Apotea is estimated to be...
New Narrative • Mar 18

Apotea is poised for growth with its online pharmacy dominance and upcoming market expansions

Online Pharmacy Market Growth: The Swedish pharmacy market is shifting online, benefiting Apotea as the dominant e-commerce player. Consumers increasingly prefer digital purchases over physical store

Earnings and Revenue Growth Forecasts

OM:APOTEA - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202810,1214324435662
12/31/20279,1553714505592
12/31/20268,1152903494272
3/31/20267,389236222323N/A
12/31/20257,205229118333N/A
9/30/20257,082263149426N/A
6/30/20256,938249157372N/A
3/31/20256,773238-14251N/A
12/31/20246,54121542206N/A
9/30/20246,30919295260N/A
12/31/20235,4558795216N/A
12/31/20224,88320-11132N/A
12/31/20214,580105146228N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: APOTEA's forecast earnings growth (21.6% per year) is above the savings rate (2%).

Earnings vs Market: APOTEA's earnings (21.6% per year) are forecast to grow faster than the Swedish market (8.4% per year).

High Growth Earnings: APOTEA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: APOTEA's revenue (11.5% per year) is forecast to grow faster than the Swedish market (-0.03% per year).

High Growth Revenue: APOTEA's revenue (11.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: APOTEA's Return on Equity is forecast to be high in 3 years time (30.4%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 14:22
End of Day Share Price 2026/05/20 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Apotea AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Niklas EkmanDNB Carnegie